Veliparib Phase III Failures Strike Blow To AbbVie's Oncology Strategy

The failure of veliparib in Phase III studies of squamous NSCLC and triple-negative breast cancer is a blow for AbbVie's oncology pipeline, but may not have implications for other PARP inhibitors in new tumor types.